A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Against Inflammation," features profiles of Asphleia Pharmaceuticals, Calistoga Pharmaceuticals, ProtAb Ltd., and Resolvyx Pharmaceuticals. Plus these Start-Ups Across Health Care: CG Therapeutics, Healionics, Mpathy Medical Devices and Pronostics.
You may also be interested in...
Pronostics is developing molecular fingerprint profiling technology that it describes as a "digital multiplex solution. Its UltraPlex platform uses microscopic aluminum microparticles, each with a unique physical barcode etched onto the surface. Applications for UltraPlex multiplexed assays include direct immunoassays, sandwich ELISAs, DNA hybridization, activity assays, receptor binding assays, and cell-based assays. The first focus for the technology is autoimmune disease, and three UltraPlex multiplexed assays, ANA, thyroid, and celiac disease, are available.
It sometimes happens that a medicine developed for one purpose is discovered to work wonderfully well in other, initially unanticipated indications. The founders of CG Therapeutics believe they can benefit from just such serendipity. The start-up company is developing a molecule first pursued at Ohio State University as a long-acting contraceptive some 30 years ago, now as a cancer vaccine meant to treat solid tumors.
Device manufacturers looking to bolster the biocompatibility of their products can now turn to Healionics, a supplier of biomaterial scaffolds designed to improve the biointegration of percutaneous or fully implanted medical devices. The company's STAR technology is a synthetic, three-dimensional matrix, similar to a thin, porous sponge. Because this biomaterial has been precisely engineered with uniform pore sizes to the approximate size of a single cell, the company says that living tissue and new blood vessels actually grow and weave into these pores.